---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-144290"
form_type: "8-K"
ticker: "ILMN"
cik: "0001110803"
company_name: "ILLUMINA, INC."
filed_at: "2025-06-23T23:59:59+00:00"
generated_at: "2026-05-18T23:22:48.237369+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Illumina to acquire SomaLogic for $350M cash plus up to $75M milestones

## Summary
- Illumina will acquire SomaLogic's aptamer-based proteomics business from Standard BioTools for $350M cash at closing, plus up to $75M in milestones and royalties.
- Transaction includes SomaLogic's SomaScan assay, CLIA/CAP lab in Boulder, CO, and ~250 employees; builds on co-development since 2021.
- Illumina expects the business to become profitable on a non-GAAP basis in 2027, with operating margins in line with Illumina by 2028.
- Closing expected in first half of 2026, subject to HSR and other customary conditions; termination fee of $14.5M under certain circumstances.
- Illumina Protein Prep (SomaScan on NGS) already has ~40 early-access customers, full availability in Q3 2025.

## SEC filing metadata
- accession: 0001193125-25-144290
- form_type: 8-K
- ticker: ILMN
- cik: 0001110803
- company_name: ILLUMINA, INC.
- filed_at: 2025-06-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1110803/000119312525144290/0001193125-25-144290-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1110803/000119312525144290/d66921d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-144290
- JSON: https://secwatch.observer/filing/0001193125-25-144290.json
- Plain text: https://secwatch.observer/filing/0001193125-25-144290.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.